242 related articles for article (PubMed ID: 20502084)
21. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.
Erkens R; Esteban Y; Towe C; Schulert G; Vastert S
Rheum Dis Clin North Am; 2021 Nov; 47(4):585-606. PubMed ID: 34635293
[TBL] [Abstract][Full Text] [Related]
22. Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome and coronary artery dilatation misdiagnosed as Kawasaki disease.
Keskindemirci G; Aktay Ayaz N; Melikoğlu N; Bornaun H; Aydoğmuş Ç; Aldemir E; Aydoğan G
Turk J Pediatr; 2015; 57(5):518-21. PubMed ID: 27411422
[TBL] [Abstract][Full Text] [Related]
23. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
24. Sustained hyperferritinemia in a child with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis - perforinopathy: case based review.
Çakan M; Aktay-Ayaz N; Gemici H; Annayev A; Çıtak A; Akçay A; Öztürk G
Turk J Pediatr; 2018; 60(5):598-603. PubMed ID: 30968645
[TBL] [Abstract][Full Text] [Related]
25. Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab.
Leurs A; Launay D; Terriou L; Hatron PY; Quartier P; Hachulla E
J Clin Rheumatol; 2019 Jun; 25(4):40-42. PubMed ID: 29485546
[No Abstract] [Full Text] [Related]
26. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
27. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
28. Clinical Course and Cytokine Profile of Systemic Juvenile Idiopathic Arthritis in a Patient with Trisomy 21.
Tanabe Y; Ota H; Kaneko S; Tsuno K; Watanabe M; Yamanishi S; Narazaki H; Fukazawa R; Shimizu M; Itoh Y
J Nippon Med Sch; 2023 Nov; 90(5):419-424. PubMed ID: 36273908
[TBL] [Abstract][Full Text] [Related]
29. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
30. Macrophage activation syndrome as a complication of juvenile rheumatoid arthritis.
An Q; Jin MW; An XJ; Xu SM; Wang L
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4322-4326. PubMed ID: 29077164
[TBL] [Abstract][Full Text] [Related]
31. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
[TBL] [Abstract][Full Text] [Related]
32. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
33. A rare case of coronary artery complication in a child with systemic juvenile idiopathic arthritis and macrophage activation syndrome: case report and literature review.
Zhang L; Wei Y; Zeng N; Wang L; Chen X; Yang J; Xiao X
Pediatr Rheumatol Online J; 2024 Jan; 22(1):4. PubMed ID: 38166957
[TBL] [Abstract][Full Text] [Related]
34. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Baris HE; Anderson E; Sozeri B; Dedeoglu F
Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
[TBL] [Abstract][Full Text] [Related]
35. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
Hedrich CM; Bruck N; Fiebig B; Gahr M
Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of systemic-onset juvenile idiopathic arthritis after treatment for presumed Kawasaki disease.
Dong S; Bout-Tabaku S; Texter K; Jaggi P
J Pediatr; 2015 May; 166(5):1283-8. PubMed ID: 25771391
[TBL] [Abstract][Full Text] [Related]
37. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Minoia F; Davì S; Horne A; Bovis F; Demirkaya E; Akikusa J; Ayaz NA; Al-Mayouf SM; Barone P; Bica B; Bolt I; Breda L; De Cunto C; Enciso S; Gallizzi R; Griffin T; Hennon T; Horneff G; Jeng M; Kapovic AM; Lipton JM; Magni Manzoni S; Rumba-Rozenfelde I; Magalhaes CS; Sewairi WM; Stine KC; Vougiouka O; Weaver LK; Davidsone Z; De Inocencio J; Ioseliani M; Lattanzi B; Tezer H; Buoncompagni A; Picco P; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
J Rheumatol; 2015 Jun; 42(6):994-1001. PubMed ID: 25877504
[TBL] [Abstract][Full Text] [Related]
38. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
[TBL] [Abstract][Full Text] [Related]
39. Systemic juvenile idiopathic arthritis: a review.
Hay AD; Ilowite NT
Pediatr Ann; 2012 Nov; 41(11):. PubMed ID: 23814932
[No Abstract] [Full Text] [Related]
40. Glucocorticoids in the management of systemic juvenile idiopathic arthritis.
Vannucci G; Cantarini L; Giani T; Marrani E; Moretti D; Pagnini I; Simonini G; Cimaz R
Paediatr Drugs; 2013 Oct; 15(5):343-9. PubMed ID: 23813411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
